| scholarly article | Q13442814 |
| P2093 | author name string | Fuchs S | |
| Quesniaux VF | |||
| Brinkmann V | |||
| Billich A | |||
| Schuler W | |||
| Strittmatter U | |||
| Zenke G | |||
| Zurini M | |||
| Enz A | |||
| Fehr T | |||
| Sanglier JJ | |||
| P2860 | cites work | Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. II. Structure elucidation, stereochemistry and physico-chemical properties | Q78238726 |
| Sanglifehrins A, B, C and D, Novel Cyclophilin-binding Compounds Isolated from Streptomyces sp. A92-308110. I. Taxonomy, Fermentation, Isolation and Biological Activity. | Q105024226 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 7165-7171 | |
| P577 | publication date | 2001-06-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action | |
| P478 | volume | 166 |
| Q40823850 | A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease |
| Q44766661 | Additional evidence of acute anti-inflammatory effects of cyclosporin A in a murine model of pleurisy. |
| Q33964203 | Creating diverse target-binding surfaces on FKBP12: synthesis and evaluation of a rapamycin analogue library |
| Q36078691 | Current status of ABO-incompatible kidney transplantation in children |
| Q59330226 | Cyclophilin A as a target in the treatment of cytomegalovirus infections |
| Q44526080 | Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression |
| Q40054442 | Cyclophilin A is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein A2, activation and nuclear translocation of ERK1/2, and chemotactic cell migration |
| Q54587476 | Cyclophilin A is required for M-CSF-dependent macrophage proliferation. |
| Q90704771 | Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis |
| Q38615621 | Cyclophilin inhibitors as a novel HCV therapy |
| Q44673393 | Cyclophilin sensitivity to sanglifehrin A can be correlated to the same specific tryptophan residue as cyclosporin A. |
| Q52573232 | CypD-mPTP axis regulates mitochondrial functions contributing to osteogenic dysfunction of MC3T3-E1 cells in inflammation. |
| Q35620073 | Dendritic cells: emerging pharmacological targets of immunosuppressive drugs |
| Q46458511 | Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A. |
| Q42716086 | Discovery of novel low-molecular-weight HIV-1 inhibitors interacting with cyclophilin A using in silico screening and biological evaluations |
| Q61582718 | Genome mining of a prenylated and immunosuppressive polyketide from pathogenic fungi |
| Q96354472 | Hepatitis C virus exploits cyclophilin A to evade PKR |
| Q39816111 | Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor |
| Q40359728 | Immunosuppressive activity of the immunophilin-binding drug Sanglifehrin A in human whole blood: potent inhibition of interleukin-6 produced by lymphocytes and monocytes |
| Q43738139 | Inhibition of cell cycle progression by the novel cyclophilin ligand sanglifehrin A is mediated through the NFkappa B-dependent activation of p53. |
| Q47403590 | Macrocycle Conformational Sampling by DFT-D3/COSMO-RS Methodology. |
| Q44632547 | Macrophage colony‐stimulating factor‐dependent macrophage proliferation is mediated through a calcineurin‐independent but immunophilin‐dependent mechanism that mediates the activation of external regulated kinases |
| Q89725380 | Medicinal chemistry strategies toward host targeting antiviral agents |
| Q27023850 | Mitochondrial permeability transition pore is a potential drug target for neurodegeneration |
| Q37460376 | Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models. |
| Q95848133 | Molecular nature and regulation of the mitochondrial permeability transition pore(s), drug target(s) in cardioprotection |
| Q33827748 | NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death |
| Q35956501 | Nuclear cyclophilins affect spliceosome assembly and function in vitro |
| Q36319209 | Peptidyl-prolyl isomerase inhibitors |
| Q47134039 | Peptidylprolyl Isomerases as In Vivo Carriers for Drugs That Target Various Intracellular Entities |
| Q91860378 | Pharmacology of mitochondrial permeability transition pore inhibitors |
| Q37898006 | Piperazic acid-containing natural products: isolation, biological relevance and total synthesis |
| Q39579921 | Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family |
| Q35108317 | Regulation of peptide bond cis/trans isomerization by enzyme catalysis and its implication in physiological processes |
| Q44049211 | Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. |
| Q46384097 | Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6 A resolution |
| Q44635536 | Substitution in position 3 of cyclosporin A abolishes the cyclophilin-mediated gain-of-function mechanism but not immunosuppression. |
| Q37596441 | Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity |
| Q36245588 | The cyclophilin repertoire of the fission yeast Schizosaccharomyces pombe. |
| Q33869604 | The cyclophilin-binding agent Sanglifehrin A is a dendritic cell chemokine and migration inhibitor |
| Q40486256 | Unexpected side chain effects at residue 8 of cyclosporin a derivatives allow photoswitching of immunosuppression. |
| Q87450517 | [Immunosuppressives to prevent rejection reactions after allogeneic corneal transplantation] |
Search more.